SARS-CoV-2 articles from across Nature Portfolio

C10, a potent non-nucleoside inhibitor targeting NSP14’s SAM-binding pocket, suppresses viral translation, exhibits immunostimulatory effects, and reverses NSP14-induced transcriptome alterations, offering promise for broader coronavirus treatment.

The COVID-19 vaccine rollout saw large global disparities in the introduction, scale-up, and evaluation of immunisation programmes. Here, the authors systematically quantify these disparities through linkage of public data sources.

mRNA vaccines seem to boost the effectiveness of an immune therapy for skin and lung cancer ― in an unexpected way.

Creating international viral biosafety guidelines are key to clearing up confusion, regaining trust and ensuring that essential research continues.

Vaccine advisers chosen by US health secretary Robert F. Kennedy Jr vote to restrict one childhood vaccine, but delay their decision on another.

The rest of the world is not following the US government’s dangerous path, and will stick with the technology that helped the world out of the COVID-19 pandemic.

Inflammation from the respiratory infections seems to be the culprit, study in mice finds.

Lonni Besançon has faced online abuse, threats and legal challenges. But he remains proud of his service to science and society.